- What's Tisch?
- Stem Cell Trial
- Get Involved
Last week your Tisch MSRCNY researchers presented six abstracts, including five posters, at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston. This was the sixth triennial event dedicated to advancing the understanding of MS and attracted over 9,000 delegates including more than one hundred exhibitors.
The presentation, "Intrathecal Administration of Mesenchymal Stem Cell-Neural Progenitors in Multiple Sclerosis: An Interim Analysis of a Phase I Clinical Trial" delivered by Dr. Sadiq, attracted well over 1,500 attendees and spawned more questions that time had allotted for. The audience was particularly intrigued when Dr. Sadiq highlighted that these mesenchymal neural progenitor cells are used within thirty minutes from the Tisch MS laboratory for administration due to the close proximity of the clinical practice to research lab at the IMSMP & Tisch MSRCNY facilities.
Over the next few weeks we will be sharing the abstracts on our website for each of the presentations made at this meeting.
"Intrathecal Administration of Mesenchymal Stem Cell-Neural Progenitors in Multiple Sclerosis: An Interim Analysis of a Phase I Clinical Trial" (posted 9/17/2014)
"Metabolomics of cerebrospinal fluid from progressive MS patients" (posted 10/3/2014)
"CSF fetuin-A is a biomarker of subclinical disease activity in progressive MS" (posted 10/3/2014)
"TGM6 is highly expressed by reactive astrocytes in the murine spinal cord during EAE and its levels correlate with the disease course" (posted 10/3/2014)
"The protection of A2aR on BBB permeability from Th1 cytokines in MS" (posted 10/3/2014)
"Exosomes released by mesenchymal stem cell populations promote differentiation and maturation of oligodendrocytes" (posted 10/3/2014)
521 West 57th Street
New York, NY 10019
Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.